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Novel delivery methods to achieve immunomodulation
David J Gould and Yuti ChernajovskyImmunomodulation in infectious diseases, cancer,
cardiovascular disease and autoimmunity can now be targeted
by sophisticated protein design, altering cellular responses by
increasing therapeutic cell numbers ex vivo and then
reimplanting, or altering cell function by gene transfer of cells ex
vivo. In the last year, vaccination has been applied to modulate
responses to autoantigens, allergens, viral or cancer antigens.
The application of these technologies has entered the clinical
arena and is having a positive impact on the treatment and
prevention of human diseases.
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Introduction
Immunomodulation can impact many pathological pro-
cesses including vaccination, autoimmunity, cancer and
transplantation. Using naturally occurring compounds
from steroids to antibodies and cytokines has been advan-
tageous for disease management. Yet, their use is limited
due to systemic effects on healthy tissue that can lead to
unwanted side effects. In this review, we want to focus on
new molecular and cellular technologies that are advan-
cing the overall aim of targeting therapy to particular
disease sites or mechanisms of disease and hence are
more specific.
Intracellular delivery systems will be required for all
molecules that have intracellular function. For example,
nucleic acid molecules including encoding genes, oligo-
nucleotides and RNA molecules must enter cells and
target the nucleus when transcription is the target.
Proteins with intracellular function require delivery into
cells. Regardless of the molecules for delivery, a common
requirement is the evasion of endosomal uptake that may
cause degradation and denaturation. Several approaches
Open access under CC BY-NC-ND license.www.sciencedirect.comare being developed that can be applied to the delivery of
all these types of molecules at disease sites. For the goal
to be fully achieved, cell-targeting strategies require still
further development.
We concentrate this review on the engineering of mol-
ecules and cells that are helping the development of
novel therapeutics (see Table 1). We are not going into
the details of the methods of gene therapy as this is
beyond the scope of this review.
Protein delivery systems
Antibodies against tumour antigens have been used for
both diagnostic and therapeutic purposes (see Figure 1a).
The cellular immune response against cancers can be
potentiated by delivering cytokines to sites of tumour
growth. For this purpose, fusion proteins between
anti-tumour antigen antibodies and cytokines (immuno-
cytokines) have been developed [1]. A humanised
anti-ganglioside GD2 antibody fused with IL-2 was
investigated in phase I clinical trials in melanoma [2]
and prostate cancer patients [3]. In both cases increased
cellular immune responses were reported.
Immunocytokines provide increased half-life to cytokines,
but the antibody moiety has a decreased half-life when
comparedwith the non-fused protein.This is probably due
to the interactions of immunocytokines with cytokine
receptors that are widely expressed throughout the body.
In this respect, engineering latent cytokines [4,5] over-
come the interaction with cytokine receptors. Latent cyto-
kines are fusion proteins between the latent-associated
peptide (LAP) from transforming growth factor (TGF) b
followed by a matrix metalloproteinase (MMP) cleavage
site and the cytokine of interest. The LAP dimer encloses
the cytokine in a shell-like structure conferring extended
half-life to the cytokine that cannot interact with its recep-
tor(s) until released fromLAPat sites of highMMPactivity
found in pathologies with local inflammation and active
tissue remodeling such as autoimmune disease, atheroscle-
rosis and cancer.
Protein transduction domains (PTDs) are peptide
sequences that can penetrate cell membranes indepen-
dent of interaction with specific receptors or transporters.
The first characterised PTD is the third a helix of
Antennapedia homeodomain protein [6] whilst a region
of HIV Tat containing a basic domain is probably the
most widely applied PTD [7] (for review on PTDs see
Reference [8]). The uptake mechanism for Tat is via a
lipid raft-dependent macropinocytosis mechanism [9].
Following cell entry Tat targets molecules to the nucleusCurrent Opinion in Pharmacology 2007, 7:445–450
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Table 1
Delivery systems
Delivery system Application References
Antibody Targeting cytokines and toxins to specific Ag expressing cells/tissues [1,2,3]
Latent molecules Specific activity of proteins at sites of MMP activity [4,5]
Protein transduction domains Intracellular delivery of proteins, DNA, RNA to any cell type [8,10,11,13]
DNA vaccination Recombinant vaccination through DNA expression of antigens [26]
Replicating viruses Specific proliferation of viruses in tumour cells [17,21]
DNA/RNA complexes Delivery of RNA or DNA to cells avoiding endosomal degradation [38,39]
T bodies T cells engineered with chimeric receptors that target them to antigen
bearing tumours or other cell types/tissues
[43,44,45,46]because of a strong nuclear localisation signal unless this
signal is overridden by a nuclear export signal in the cargo
molecule. In view of PTDs’ lack of immunogenicity, and
versatility as carriers of a variety of molecules (proteins,
peptides, siRNA, DNA–protein complexes and viruses)
of unlimited size, their clinical application seems likely in
the near future. The versatility of these molecules is
illustrated in a recent study where PTDs were used to
deliver pre-mRNA to correct aberrant splicing of a geneFigure 1
Schematic representation of the structure of antibodies, scFv and chimeric
with its variable heavy (VH), variable light (VL) domains that comprise the an
regions (CH and CL). The whole structure is kept together by disulfide bond
fused via a 15 aminoacid linker of the sequence (GGGGS)3. Panel c shows
and is normally linked to the cytoplasmic signaling domain of a TCR chain s
Current Opinion in Pharmacology 2007, 7:445–450[10]. Also Bim, an antagonist of Bcl-2-mediated cell
survival, was delivered to tumour cells with Tat that
significantly slowed down tumour growth in murine
models of pancreatic cancer and melanoma [11]. Another
potential strategy for cancer treatment utilising a PTD is
delivery of HSV-TK fused with Tat (TK-Tat), and in this
in vitro study TK-Tat localised to the nucleus was stable
and cells were sensitive to ganciclovir treatment with
good bystander killing observed [12]. PTDs have beenscFv signaling receptors. Panel a shows the structure of an antibody
tigen recognition/binding site with their respective constant
s. Panel b shows the structure of a scFv where the VH and VL are
the structure of scFv chimeric receptor where the scFv is extracellular
uch as the FcRg or the z chain through a spacer or hinge region.
www.sciencedirect.com
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of inflammation; for example, the delivery of theTat-IkBa
superrepressor in a rat pleurisymodel caused a reduction in
both leucocyte recruitment and production of proinflam-
matory cytokines [13].One interesting strategy is theuseof
a short amphipathic peptide carrier, Pep-1, which can be
linked non-covalently to cargo molecules through Fmoc,
which then dissociates immediately after it has crossed the
cell membrane [14] and the liberated cargo can then
distribute with normal tropism without influence from
the attached PTD.
Human papilloma virus (HPV) has proven hard to eradi-
cate because of ineffective means of in vitro culture.
Cloning of the HPV capsid gene (L1) and its expression
in heterologous systems [15] has allowed the develop-
ment of effective vaccines. Hence, prophylactic vaccina-
tion to HPV types 6/11/16 and18 to prevent cervical
cancer is becoming a reality [16].
New viral gene delivery systems
Somatic gene therapy was originally thought to be safer
using non-replicating viruses. However, for cancer treat-
ment scientists have now developed attenuated viruses
that are capable of replicating more efficiently in cancer
cells than in normal cells. These oncolytic viruses could in
principle infect neighbouring cancer cells and lyse them
sparing the normal tissue. Awide variety ofRNAandDNA
viruses are being investigated [17]. Replicating poxvirus
can deliver antiangiogenic factors both as secreted factors
or as shRNA [18,19] or cytokines such as GM-CSF [20].
Recently, the data of a phase I clinical trial in prostate
cancer using intravenous injection of a replication-selec-
tive, prostate-specific antigen-targeted oncolytic adeno-
virus were published with some positive results [21].
The use of oncolytic viruses, the relevance of the animal
models and theenvironmental safety issues involved raised
some concerns [22]. The immune system appears to be
dealing quite effectively with these oncolytic viruses
because most humans are preimmune to these viruses
either via natural exposure or by vaccination. Whether
the antiviral immune response will allow for effective
cancer therapy will need to be resolved in clinical trials.
Non-viral delivery systems
PlasmidDNA has no innate mechanism to enter cells, but
direct injection in skeletal muscle achieves transfection
and gene expression in most species from rodents [23] to
humans [24]. This expression has led to the effective
application of plasmid vectors in numerous vaccination
studies conducted in rodents. DNA-based vaccines have
several advantages including their simple preparation and
stability. Vaccination is more flexible because the plasmid
encoding the antigen can be combined with other genes
that modify the immune response. Plasmid DNA also has
immunostimulatory properties due to unmethylated CpGwww.sciencedirect.comrepeats that interact with TLR9 receptors expressed on
antigen-presenting cells (APC), although this is not a
prerequisite for vaccination as responses are also observed
in TLR9-knockout mice [25]. Interestingly, the effective-
ness ofDNAvaccines in small animals has not translated to
primates and humans and proof of activity in clinical trials
has only recently been reported. In a phase I trial a DNA
vaccine for bird flu was shown to be safe and achieved
antibody responses at tested doses [26]. Transfection of
plasmid DNA in skeletal muscle is efficiently enhanced in
rodents by the use of electroporation that opens pores in
the cells to permit direct entry of DNA [27]. Electropora-
tion can enhance DNA vaccination [28], but there are few
reports using electroporation in large animals. However,
hydrodynamic delivery of plasmidDNA or siRNA into the
vasculature of an occluded limb has proven equally effec-
tive in primates and rodents [29].
Nucleic acid molecules also need to be delivered intra-
cellularly for function to the nucleus (for gene transcrip-
tion, or for transcriptional decoy effects) or to the
cytoplasm for inhibition of RNA translation or to target
mRNA degradation (antisense RNA, ribozymes). RNA
interference (RNAi) is an endogenous mechanism
whereby double stranded RNA is processed by the
RNAse III-like protein Dicer to produce short interfering
RNA (siRNA) that are incorporated into the RNA-
induced silencing complex (RISC) [30]. Synthetic siRNA
are structurally related to endogenous microRNAs
(miRNA) and can be used for sequence specific silencing.
Bevasiranib, an siRNA targeting VEGFmRNA, is already
in phase II clinical trials for the treatment of wet age-
related macular degeneration [31]. These small mol-
ecules were applied in a variety of experimental models
in saline, complexed with lipids or conjugated with mol-
ecules for improved pharmacokinetics or targeting [32].
Another interesting aspect of these molecules relevant to
immunomodulation is their interaction with Toll-like
receptor (TLR)-7 through which they can co-deliver an
immunostimulatory response. In a recent study, immu-
nostimulation was further enhanced with an siRNA tar-
geting expression of IL-10 in combination with the TLR-
7 stimulation by the molecule [33].
siRNA was used in arthritis models for targeting TNFa.
siRNA was delivered to knee joints in combination with
electroporation [34,35] or systemically complexed with
cationic liposomes [36]. Both approaches required re-
administration. This transient action is clearly a short-
coming for long-term effects in the treatment of chronic
diseases such as rheumatoid arthritis. An alternative is the
use of short hairpin RNA (shRNA) molecules expressed
long term from gene delivery vectors. shRNA are
additionally processed in the nucleus by an RNAse III
protein (Drosha) producing pre-miRNA which are
exported to the cytoplasm for further processing by Dicer
to produce mature miRNA.Current Opinion in Pharmacology 2007, 7:445–450
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mRNA sequences. Their design is more complex than
siRNA. Recently, a hammerhead ribozyme targeting
TNFa was shown to inhibit a model of arthritis when
delivered intravenously before onset of the disease [37].
Naked DNA and RNA molecules can be combined with
a variety of polycations in polyplexes for delivery to
cells. The polycations used have different character-
istics including ease of DNA unpackaging that is influ-
enced by their molecular weight, toxicity, stability and
ability to facilitate endosomal escape. Polyethylenimine
(PEI), for example, is a polycation with strong endosome
escape properties. To decrease the toxicity of polyca-
tions and retain their stability, reducible polycations are
used that are specifically cleaved within cells to release
the DNA. Synthetic vectors based on reducible (thiol-
containing) polycations consisting of histidine and poly-
lysine residues were shown to efficiently deliver DNA,
mRNA and siRNA in a variety of different cells [38].
The reducible approach has also been used to coat PEI
complexes [39].
To target liposomes, phage peptide libraries are used to
screen for tissue-binding peptides in vivo, for example, in
cancer [40] or synovial endothelium in arthritis [41].
These selected peptides can be conjugated to liposomes
in order to target their cell of interest.
Cell delivery systems
The principle of immunosurveillance has always been
central to immunotherapy approaches for the treatment of
cancer. Despite the myriad of mechanisms by which
cancer cells evade immunosurveillance, it has now been
shown that infusion of autologous tumour antigen-specific
T cells expanded ex vivo are therapeutic [42].
Another method for T cell therapy of cancer is the de-
velopment of T bodies [43] in which chimeric receptors
with extracellular scFv (see Figure 1b) of antibodies
against tumour antigens are grafted onto the cytoplasmic
and signaling domains of T cell receptor (TCR) subunits
(see Figure 1c). The direct recognition of antigen by the
scFv obviates the need for antigen processing and pres-
entation by the major histocompatibility complex. In a
clinical trial using T bodies, targeting of the tumour sites
was poor and survival of the engineered cells very limited
[44]. This may be due in part to the fact that the scFv used
was of mouse origin. Similar work has also been done by
cloning a and b chains of TCR from tumour infiltrating
lymphocytes with some degree of success in melanoma
[45,46]. It is of interest that the fate of the endogenous
TCR chains of the transduced cells is unknown. Whether
the endogenous TCR chains recognise autoantigens by
themselves or by combination with the transduced TCR
chains could have consequences for autoimmunity and
needs a long-term follow-up of these patients.Current Opinion in Pharmacology 2007, 7:445–450Mesenchymal stromal cells (MSC) have immunosuppres-
siveproperties.Transplantation ofMSChasbeen shown to
inhibit steroid-resistant grade III–IV graft versus host
disease (GvHD) in patients receiving allogeneic stem
cell therapy [47,48]. MSC seem to affect the cytokine
secretionprofile of dendritic cells (DCs), naive andeffector
T helper cells, and natural killer (NK) cells to induce a
more anti-inflammatory or tolerant phenotype [49].
GvHD is mediated by T cells from donor origin. T cells
can be retrovirally transduced, after cell cycle activation
ex vivo with anti-CD28/CD3 or phytohaemaglutinin, to
express the ‘suicidal’ gene thymidine kinase fromHerpes
simplex virus (HSV tk) that renders dividing T cells
sensitive to ganciclovir, and this approach has been used
in clinical trials [50,51]. Recently, it has been shown that
using IL-7-mediated proliferation of T cells preserves
the effector function of T cells more effectively than
TCR-mediated protocols for viral transduction [52].
Conclusions
The ingenuity of scientists and the exponential growth in
the understanding of molecular mechanisms involved in
different pathologies have increased substantially the pos-
sibilities for immunomodulation. The potential of novel
approaches such as gene therapy and drug design enable
targeting of therapeutics with better therapeutic index.
The limitation of these therapies resides in our better
understanding of the long-term outcome of delivering
biologicals and manipulating the immune system. The
immune system is finely tuned in health to react to foreign
pathogens and oncogenic changes of cells in the body.
Tilting the immune system with therapeutic agents to
behave in a particular way is not without consequences.
The challenge for immunomodulating therapies will be to
obtain long-lived therapeutic outcomes with shorter thera-
peutic interventions. This may require the combination of
immunotherapies alone or with stem cell therapies.
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